Literature DB >> 2439802

Respiratory tolerance of bisoprolol and metoprolol in asthmatic patients.

J W Lammers, H T Folgering, C L van Herwaarden.   

Abstract

The respiratory tolerance of the beta 1-adrenoceptor-selective blockers bisoprolol and metoprolol was investigated in eight male asthmatic patients. The interaction with the bronchodilatory effect of the beta 2-adrenoceptor-selective agonist terbutaline was studied to compare the beta 1-adrenoceptor selectivity of 10 and 20 mg bisoprolol and 100 mg metoprolol. The three beta-blocker doses caused a significant decrease in heart rate at rest. Systolic and diastolic blood pressure decreased significantly after administration of 20 mg bisoprolol and 100 mg metoprolol, but not after administration of 10 mg bisoprolol. Both beta-blockers caused an increase in bronchoconstriction, as measured by a significant fall in peak expiratory flow rate (PEFR). Only 10 mg bisoprolol caused a significant decrease in vital capacity (VC) and forced expiratory volume in 1 s (FEV1). Bronchoconstriction was rapidly reversed by inhalation of terbutaline in all patients. There were no differences between the responses of FEV1, VC, and PEFR to terbutaline with any of the beta-blockers, indicating a good degree of beta 1-adrenoceptor selectivity of 10 and 20 mg bisoprolol and 100 mg metoprolol in humans.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 2439802     DOI: 10.1097/00005344-198511001-00012

Source DB:  PubMed          Journal:  J Cardiovasc Pharmacol        ISSN: 0160-2446            Impact factor:   3.105


  10 in total

1.  Cost-benefit analysis of the detection of prescribing errors by hospital pharmacy staff.

Authors:  Patrica M L A van den Bemt; Maarten J Postma; Eric N van Roon; Man-Chie C Chow; Roel Fijn; Jacobus R B J Brouwers
Journal:  Drug Saf       Date:  2002       Impact factor: 5.606

Review 2.  The applied pharmacology of beta-adrenoceptor antagonists (beta blockers) in relation to clinical outcomes.

Authors:  J D Fitzgerald
Journal:  Cardiovasc Drugs Ther       Date:  1991-06       Impact factor: 3.727

Review 3.  Newer beta blockers and the treatment of hypertension.

Authors:  D McAreavey; R Vermeulen; J I Robertson
Journal:  Cardiovasc Drugs Ther       Date:  1991-06       Impact factor: 3.727

4.  A dose-ranging study to evaluate the beta 1-adrenoceptor selectivity of bisoprolol.

Authors:  B J Lipworth; N A Irvine; D G McDevitt
Journal:  Eur J Clin Pharmacol       Date:  1991       Impact factor: 2.953

Review 5.  Bisoprolol. A preliminary review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in hypertension and angina pectoris.

Authors:  S G Lancaster; E M Sorkin
Journal:  Drugs       Date:  1988-09       Impact factor: 9.546

6.  Evaluation of the safety and efficacy of metoprolol infusion for children and adolescents with hypertensive crises: a retrospective case series.

Authors:  Rola Saqan; Hanan Thiabat
Journal:  Pediatr Nephrol       Date:  2017-07-21       Impact factor: 3.714

7.  Hemodynamic evaluation of bisoprolol after coronary artery surgery in patients with altered left ventricular function.

Authors:  M Goldstein; J L Vincent; J L Le Clerc; A d'Hollander; C Melot; R J Kahn
Journal:  Cardiovasc Drugs Ther       Date:  1991-06       Impact factor: 3.727

8.  Comparison of the effects of nadolol and bisoprolol on noradrenaline-evoked venoconstriction in man in vivo.

Authors:  A H Abdelmawla; R W Langley; E Szabadi; C M Bradshaw
Journal:  Br J Clin Pharmacol       Date:  1998-03       Impact factor: 4.335

9.  Comparison of the effects of nadolol and bisoprolol on the isoprenaline-evoked dilatation of the dorsal hand vein in man.

Authors:  A H Abdelmawla; R W Langley; E Szabadi; C M Bradshaw
Journal:  Br J Clin Pharmacol       Date:  2001-06       Impact factor: 4.335

Review 10.  Evolution of β-blockers: from anti-anginal drugs to ligand-directed signalling.

Authors:  Jillian G Baker; Stephen J Hill; Roger J Summers
Journal:  Trends Pharmacol Sci       Date:  2011-03-21       Impact factor: 14.819

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.